NC 1100

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592590

CAS#: 93035-33-7

Description: NC 1100 is a calcium channel antagonist.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-27. Prices are subject to change without notice.

NC 1100 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 592590
Name: NC 1100
CAS#: 93035-33-7
Chemical Formula: C27H34Cl2N2O3
Exact Mass: 504.1946
Molecular Weight: 505.48
Elemental Analysis: C, 64.16; H, 6.78; Cl, 14.03; N, 5.54; O, 9.50

Synonym: NC 1100; NC-1100; NC1100

IUPAC/Chemical Name: 1-Piperazineethanol, alpha-(3,4-dimethoxyphenyl)-4-(diphenylmethyl)-, dihydrochloride


InChi Code: InChI=1S/C27H32N2O3.2ClH/c1-31-25-14-13-23(19-26(25)32-2)24(30)20-28-15-17-29(18-16-28)27(21-9-5-3-6-10-21)22-11-7-4-8-12-22;;/h3-14,19,24,27,30H,15-18,20H2,1-2H3;2*1H


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Miyake N, Takayanagi I. Stereoselectivity of NC-1100, a Ca-entry blocker. Gen Pharmacol. 1990;21(2):261-3. PubMed PMID: 2332145.

2: Matsumura T, Furuichi H, Izumi J, Kamatsuka Y, Takei M, Nakata N, Ito S, Suda H, Kizaki K, Kurimoto T. [Effects of NC-1100, a calcium channel blocker, on experimental cerebral ischemia/anoxia in rodents]. Nihon Yakurigaku Zasshi. 1993 Mar;101(3):177-86. Japanese. PubMed PMID: 8486322.

3: Sadoshima S, Ibayashi S, Nakane H, Okada Y, Ooboshi H, Fujishima M. Attenuation of ischemic and postischemic damage to brain metabolism and circulation by a novel Ca2+ channel antagonist, NC-1100, in spontaneously hypertensive rats. Eur J Pharmacol. 1992 Dec 2;224(2-3):109-15. PubMed PMID: 1468503.

4: Hashimoto T, Kimori M, Nakamura Y, Kuriyama K. Effect of NC-1100 [1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl) ethanol dihydrochloride] on gamma-aminobutyric acid (GABA) metabolism in rat brain: analysis using stroke-prone spontaneously hypertensive rat. Jpn J Pharmacol. 1989 Jun;50(2):131-9. PubMed PMID: 2770051.

5: Kuribara H, Tadokoro S. [Behavioral effects of NC-1100, 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl) ethanol dihydrochloride--on ambulatory activity, discrete lever-press response and shuttle avoidance response in mice]. Nihon Yakurigaku Zasshi. 1989 Apr;93(4):245-53. Japanese. PubMed PMID: 2744654.

6: Tanabe K, Kinoshita Y, Tokuyoshi K, Houri D, Kimishima K. [Effects of 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl)ethanol dihydrochloride (NC-1100) on the central nervous system]. Nihon Yakurigaku Zasshi. 1991 Nov;98(5):357-68. Japanese. PubMed PMID: 1813367.

7: Miyake N, Wakamori M, Akaike N. A new type of Ca2+ channel blocker, NC-1100, inhibits the low- and high-threshold Ca2+ currents in the rat CNS neurons. Brain Res. 1992 Dec 11;598(1-2):215-20. PubMed PMID: 1486482.

8: Kushiku K, Ohba M, Araki T, Mikagi T, Katsuragi T, Furukawa T. Cardiovascular effects of 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl) ethanol and possible mechanisms involved. Arzneimittelforschung. 1989 Apr;39(4):458-63. PubMed PMID: 2751731.

9: Nishijo H, Kuze S, Ono T, Tabuchi E, Endo S, Kogure K. Calcium entry blocker ameliorates ischemic neuronal damage in monkey hippocampus. Brain Res Bull. 1992 Sep-Oct;29(3-4):519-24. PubMed PMID: 1393625.

10: Takayanagi I, Koike K, Miyake N, Sato R, Yamada K. Selectivity of cerebral vasodilators on basilar arteries. Gen Pharmacol. 1986;17(4):505-7. PubMed PMID: 3758658.

11: Nishijo H, Tabuchi E, Ono T, Fukuda M, Kuze S, Endo S. Physiological results of monkey brain ischemia, and protection by a calcium blocker. Brain Res Bull. 1995;37(1):89-101. PubMed PMID: 7606483.

12: Nomura Y, Yamakawa T, Nishioka K, Omura T, Miyake N, Masaki M, Nohira H. Synthesis and structure-activity relationships of 2-(4-benzhydryl-1-piperazinyl)-1-phenylethanols as new calcium blockers. Chem Pharm Bull (Tokyo). 1995 Feb;43(2):241-6. PubMed PMID: 7537178.

13: Miyake N, Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K. Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000 Mar;82(3):265-8. PubMed PMID: 10887958.

14: Tamura R, Nakada Y, Nishijo H, Miyake N, Ono T. Ameliorative effects of tamolarizine on place learning impairment induced by transient forebrain ischemia in rats. Brain Res. 2000 Jan 17;853(1):81-92. PubMed PMID: 10627311.

15: Izumiyama K, Kogure K. Prevention of delayed neuronal death in gerbil hippocampus by ion channel blockers. Stroke. 1988 Aug;19(8):1003-7. PubMed PMID: 2456632.